Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback